CYP2D6 and psychotic disorder: Patients were eligible for inclusion if they were already diagnosed with a non-affective psychotic disorder, and were genotyped a posteriori, during the “Genetic Risk and Outcome of Psychosis” (GROUP) study for which CYP2D6 phenotype was not a main outcome.